BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36641751)

  • 1. Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex.
    Wang X; Xie Q; Ji Y; Yang J; Shen J; Peng F; Zhang Y; Jiang F; Kong X; Ma W; Liu D; Zheng L; Qing C; Lang JY
    Cell Rep; 2023 Jan; 42(1):111972. PubMed ID: 36641751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GTPase KRAS suppresses the p53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells.
    Yang H; Xiang S; Kazi A; Sebti SM
    J Biol Chem; 2020 Mar; 295(10):3055-3063. PubMed ID: 32001619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riok1, A Novel Potential Target in MSI-High p53 Mutant Colorectal Cancer Cells.
    Shechter S; Ya'ar Bar S; Khattib H; Gage MJ; Avni D
    Molecules; 2023 May; 28(11):. PubMed ID: 37298928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis, necroptosis and autophagy in colorectal cancer: Associations with tumor aggressiveness and p53 status.
    Sakanashi F; Shintani M; Tsuneyoshi M; Ohsaki H; Kamoshida S
    Pathol Res Pract; 2019 Jul; 215(7):152425. PubMed ID: 31097354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
    Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
    PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oleic acid-induced metastasis of KRAS/p53-mutant colorectal cancer relies on concurrent KRAS activation and IL-8 expression bypassing EGFR activation.
    Shen CJ; Chan RH; Lin BW; Li NC; Huang YH; Chang WC; Chen BK
    Theranostics; 2023; 13(13):4650-4666. PubMed ID: 37649607
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of KRAS mutations and p53 expression on the postoperative prognosis of patients with colorectal cancer.
    Wang L; Lin S; Yang C; Cai S; Li W
    Mol Genet Genomic Med; 2022 Jul; 10(7):e1905. PubMed ID: 35686701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
    Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
    Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels.
    Iyer NG; Chin SF; Ozdag H; Daigo Y; Hu DE; Cariati M; Brindle K; Aparicio S; Caldas C
    Proc Natl Acad Sci U S A; 2004 May; 101(19):7386-91. PubMed ID: 15123817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.
    Liao W; Overman MJ; Boutin AT; Shang X; Zhao D; Dey P; Li J; Wang G; Lan Z; Li J; Tang M; Jiang S; Ma X; Chen P; Katkhuda R; Korphaisarn K; Chakravarti D; Chang A; Spring DJ; Chang Q; Zhang J; Maru DM; Maeda DY; Zebala JA; Kopetz S; Wang YA; DePinho RA
    Cancer Cell; 2019 Apr; 35(4):559-572.e7. PubMed ID: 30905761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
    Wang J; Hu K; Guo J; Cheng F; Lv J; Jiang W; Lu W; Liu J; Pang X; Liu M
    Nat Commun; 2016 May; 7():11363. PubMed ID: 27193833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells.
    Zhang S; Zhou L; El-Deiry WS
    Mol Cancer Res; 2022 Apr; 20(4):622-636. PubMed ID: 34992144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant p53 in colon cancer.
    Nakayama M; Oshima M
    J Mol Cell Biol; 2019 Apr; 11(4):267-276. PubMed ID: 30496442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. USP5-Beclin 1 axis overrides p53-dependent senescence and drives Kras-induced tumorigenicity.
    Li J; Wang Y; Luo Y; Liu Y; Yi Y; Li J; Pan Y; Li W; You W; Hu Q; Zhao Z; Zhang Y; Cao Y; Zhang L; Yuan J; Xiao ZJ
    Nat Commun; 2022 Dec; 13(1):7799. PubMed ID: 36528652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.
    Orue A; Chavez V; Strasberg-Rieber M; Rieber M
    BMC Cancer; 2016 Nov; 16(1):902. PubMed ID: 27863474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.
    Morton JP; Timpson P; Karim SA; Ridgway RA; Athineos D; Doyle B; Jamieson NB; Oien KA; Lowy AM; Brunton VG; Frame MC; Evans TR; Sansom OJ
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):246-51. PubMed ID: 20018721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of serum p53 antibody according to KRAS status in metastatic colorectal cancer patients.
    Daitoku N; Miyamoto Y; Sakamoto Y; Tokunaga R; Hiyoshi Y; Nagai Y; Iwatsuki M; Iwagami S; Yoshida N; Baba H
    Int J Clin Oncol; 2020 Apr; 25(4):651-659. PubMed ID: 31834556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
    Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
    J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK inhibition suppresses metastatic progression of KRAS-mutated gastric cancer.
    Yamasaki J; Hirata Y; Otsuki Y; Suina K; Saito Y; Masuda K; Okazaki S; Ishimoto T; Saya H; Nagano O
    Cancer Sci; 2022 Mar; 113(3):916-925. PubMed ID: 34931404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
    Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
    Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.